Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

"Competing interests The authors declare the following potential conflicts of interest: EKM: consulting or advisory role, honoraria, research funding, and travel accommodations/expenses from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda. TH and UB: no competing interests. HJS: advisory role or honoraria from AbbVie, Amgen, Bristol Myers Squibb/Celgene, Chugai, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Roche, Sanofi, Sebia, TAD, and Takeda; travel accommodation/expenses from Amgen, Bristol Myers Squibb/ Celgene, GlaxoSmithKline, Janssen-Cilag, and Sanofi. SZ: consulting or advisory role for Janssen-Cilag, Bristol Myers Squibb, Sanofi, Oncopeptides, and Takeda (all payments to the institution); research funding from Janssen-Cilag and Takeda. MSR: consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Novartis, Roche, and Sanofi; honoraria from AbbVie and GlaxoSmithKline; research funding from Novartis and Sanofi. MM: consulting or advisory role for AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; honoraria from Amgen, Bristol Myers Squibb, Janssen, and Takeda; research funding from Incyte; travel accommodation/expenses from Amgen. LP honoraria from Sanofi, GlaxoSmithKline, and Pfizer. KM: honoraria from Amgen, Bristol-MyersSquibb/Celgene, Janssen, Takeda, Sanofi, GlaxoSmithKline, and Pfizer. PB: no competing interests. MB: consulting or advisory role for Janssen, Celgene/Bristol Myers Squibb, Amgen, Sanofi, Takeda, and Menarini; speaker’s bureau for Amgen, Takeda, Sanofi, and Celgene/Bristol Myers Squibb. IWB: no competing interests. JD: consulting or advisory role for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda, Celgene, and Roche; travel accommodation/expenses from Roche, Celgene, and Bristol Myers Squibb. BB: honoraria from Janssen, GlaxoSmithKline, Amgen, and Sanofi. RF: honoraria from Bristol Myers Squibb/Celgene, Janssen, Sanofi, and GlaxoSmithKline; consulting or advisory role for Bristol Myers Squibb/Celgene, Janssen, and GlaxoSmithKline; travel accommodations/expenses from Bristol Myers Squibb/Celgene, Janssen, and GlaxoSmithKline. PR and BvdH: no competing interests. MH: consulting or advisory role for Amgen, Bayer Vital, Bristol Myers Squibb/Celgene, Gilead, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Roche, and Takeda; invitation as speaker for Novartis. IvM: consulting or advisory role for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; honoraria from Sanofi; travel accommodations/expenses from Takeda. UG: stock and other ownership interests for Biontech; honoraria from Boehringer Ingelheim, Amgen, Astra Zeneca, Bristol Myers Squibb/Celgene, MSD Oncology, Sanofi Aventis, Fujifilm, Novartis, and Celltrion; consulting or advisory role for Amgen, MSD oncology; research funding from Ipsen (to the institution), Macrogenics (to the institution); travel accommodations/expenses from Boehringer Ingelheim and GlaxoSmithKline. CM-T: research funding from Pfizer and BioliveRx. MB: honoraria from AbbVie, Amgen, Bristol-Myers Squibb/Celgene, Janssen, Novartis, and Sanofi. CS: honoraria from AbbVie, Amgen, Bristol Myers Squibb, Glaxo Smith Kline, Janssen, Pfizer, Oncopeptides, Sanofi, and Takeda; travel accommodation/expenses from Bristol Myers Squibb, Janssen, Novartis, and Takeda; research funding from Janssen, Novartis, and Takeda. MAD: honoraria from Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, BeiGene, and Sanofi; consulting or advisory role for Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, BeiGene, and Sanofi. JH: consulting or advisory role for Adaptive, Amgen, Axxes Network, Bristol Myers Squibb/Celgene, Glaxo Smith Kline, Janssen, Oncopeptides, Oncotracker, Sanofi, and Skyline; invited talks for Amgen, Beigene, Beijing Medical Award Foundation, Curio Science, and Janssen. KCW: honoraria from Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda; consulting or advisory role for Abbvie, Amgen, Adaptive Biotech, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda; research funding from Amgen (to the institution), Bristol Myers Squibb/Celgene (to the institution), Janssen (to the institution), and Sanofi (to the institution). MC: consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb, GSK, Janssen, Pfizer, and Sanofi; speaker’s bureau for Bristol Myers Squibb and Janssen. PS: consulting or advisory role for Celgene/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi; research funding from Celgene/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi. HG: consulting for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, and Janssen; honoraria from Amgen, Bristol Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, and Novartis; research funding from Amgen, Bristol Myers Squibb, Celgene, Chugai, Incyte, Janssen, Molecular Partner, MSD, Mundipharma, and Novartis; grants from Amgen, Celgene, Chugai, Janssen, and Johns Hopkins University."

"Funding The HOVON-65/GMMG-HD4 trial was supported by the German Federal Ministry of Education and Research (BMBF), the Dutch Cancer Foundation, Janssen-Cilag-Ortho Biotech, Novartis, Amgen, Chugai, and Roche. The GMMG-MM5 trial was supported by Celgene, Janssen-Cilag, Chugai, and Binding Site. The GMMG-HD6 trial was supported by BMS, Celgene, and Chugai. The EMN02/HO95 trial was supported by Janssen and Celgene. The GMMG-HD7 trial was supported by Sanofi and BMS/Celgene. Open Access funding enabled and organized by Projekt DEAL."